Porphyrin metabolism disease

This study is for people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), rare conditions that cause severe pain and skin reactions to sunlight. The purpose is to check the long-term safety of an oral medication called dersimelagon. About 301 participant…

This registry will follow 20 people in China with progressive familial intrahepatic cholestasis (PFIC) who are taking odevixibat (Bylvay) as part of their normal care. The goal is to see how safe the drug is over the long term and how well it controls symptoms like severe itching…

This expanded access program provides bitopertin (DISC-1459) to patients aged 12 and older with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) who have no satisfactory treatment options in the US. The goal is to offer access and gather safety information. Pa…

This registry will follow 10 people with progressive familial intrahepatic cholestasis (PFIC) in South Korea who are taking odevixibat (Bylvay). The goal is to see how safe and effective the drug is over the long term in real-world use. Researchers will track side effects and how…

This study follows 230 children with Alagille syndrome or progressive familial intrahepatic cholestasis (PFIC) who are taking Livmarli, a drug to reduce bile buildup and itching. Researchers will monitor side effects, liver function, and long-term outcomes like need for transplan…

This study is testing whether eating a diet rich in carbohydrates (60-65% of daily calories) can help people with acute intermittent porphyria (AIP), a rare genetic disorder that causes severe attacks of pain and other symptoms. Fifty adults with AIP will try two different diet p…

This early-phase trial tests an oral drug called ATL-001 (ciclopirox) in 6 adults with congenital erythropoietic porphyria (CEP), a rare condition that causes severe skin damage from sunlight. The study measures whether the drug reduces skin lesions, fatigue, and other symptoms o…

This study tests whether giving oral zinc sulfate and ursodeoxycholic acid alongside standard light therapy can help clear jaundice faster in newborns. About 80 babies with non-hemolytic jaundice will receive one of two doses of zinc, or the liver drug UDCA, plus phototherapy. Th…

This early-stage trial tests a new method to diagnose and treat severe jaundice in newborns. The method uses a non-invasive breath test (ETCOc) to detect hemolysis, a common cause of jaundice. Researchers will compare this approach to standard care in 250 newborns to see if it re…

This study looks at 116 newborns with jaundice to find the best way to use phototherapy (light treatment). It compares different light intensities and whether taking breaks during treatment works as well as continuous light. The goal is to make treatment more effective and allow …

This study tests whether early physiotherapy, taught to parents, can improve movement and development in babies at risk for problems like cerebral palsy. Fifty infants from the NICU will be randomly assigned to get either the special program or standard care. Researchers will mea…

This study is testing a device that measures carbon monoxide in a newborn's breath to help diagnose jaundice. Jaundice is common in newborns and can be serious if not treated. The device is non-invasive and could replace or reduce the need for blood tests. Researchers will measur…

This study tests whether adding a medicine called ursodeoxycholic acid (UDCA) to standard light therapy helps clear jaundice faster in newborns. About 70 babies born at 34 weeks or later with jaundice will be randomly assigned to receive either light therapy alone or light therap…

This study follows 1,500 people with porphyria over many years to learn how the disease progresses, what symptoms appear, and how it affects pregnancy and lifespan. Researchers will collect medical records and lab results to create a clearer picture of the condition. No new treat…

This study looks at how common tooth staining is in children who had very high bilirubin levels (jaundice) early in life. Researchers will check 120 children with certain liver conditions to see if their teeth are discolored and whether that affects their daily life. The goal is …

This observational study is gathering information on how erythropoietic protoporphyria (EPP) and X-linked porphyria (XLP) affect people aged 12 and older. Over 6 months, researchers will track symptoms, light exposure, and blood levels of protoporphyrin IX (PPIX) in 50 participan…

This study creates a Canadian registry for children under 18 with Alagille syndrome or genetic intrahepatic cholestasis, rare liver conditions that cause bile buildup. Researchers will collect health data from medical records over time to understand how these diseases progress an…

This study is a global registry that will follow about 150 people with acute hepatic porphyria (AHP) over time. Researchers will collect information on how the disease progresses, how it is managed in real-world settings, and the safety and effectiveness of approved treatments li…

This study is using advanced whole-genome sequencing to find hidden genetic causes of cholestatic liver disease in adults whose condition remains unexplained after standard tests. Researchers will compare the DNA of 60 affected adults to a large group of healthy controls. The goa…

This study is monitoring 50 children in Japan with Alagille syndrome (ALGS) or progressive familial intrahepatic cholestasis (PFIC) who are taking the drug Livmarli (maralixibat). Researchers are using a national registry to track how many children develop liver problems and how …